Concern Foundation provides critical funding to post-doctoral and early-career cancer researchers to advance understanding, prevention and treatment of cancer. Concern focuses on ensuring donor dollars are used effectively to identify causes of and cures for cancer.
Concern Foundation’s recent awards show a clear emphasis on early-career cancer science, with a single project reaching $225,000 for Children’s Hospital Los Angeles USC on fusion-positive rhabdomyosarcoma and metastatic invasion. Across its grantmaking, the foundation backs laboratory and translational research that can inform cancer genetics, cell biology, immunology, and immunotherapy. Its named programs reinforce that pattern: the Concern Foundation Grant Program supports promising early-career scientists with seed funding, while the Conquer Cancer Now Award provides 2-year support for post-doctoral and early-career researchers. The foundation also funds work tied to specific cancer types and patient groups. Recent support includes pediatric brain tumors at Childrens Hospital Los Angeles, breast cancer immune-response research at the University of Southern California and USC Norris Comprehensive Cancer Center, and projects on pancreatic, ovarian, lung, cervical, melanoma, and glioblastoma biology. That mix suggests a funder that combines investigator development with disease-focused discovery research. Grants are generally made to affiliated research institutions in the United States, with awards appearing at both the $60,000 and $75,000 levels and above for selected projects. Concern Foundation also supports a summer oncology research fellowship program, linking research funding with workforce development.
In pediatric oncology, Concern Foundation backed Children’s Hospital Los Angeles with $150,000 for novel molecular mechanisms of P1D1 function in pediatric brain tumors, and another $90,000 for a summer oncology research fellowship program. The foundation also supported neuroblastoma work at the same institution with a $75,000 grant focused on chromosome 17q gain-mediated tumorigenesis. Breast cancer and immune response are another visible thread. The University of Southern California received $100,000 for ethnic differences among breast cancer patient immune responses, and USC Norris Comprehensive Cancer Center received $100,000 for ethnic differences in immune responses among breast cancer patients. Concern Foundation also funds metastasis, invasion, and tumor microenvironment research. Temple University received $75,000 for the role of chemotherapy in awakening dormant tumor cells and metastatic relapse, while Oregon Health and Science University received $75,000 to reprogram suppressive regulatory T cells in the tumor microenvironment. At Washington University, a $75,000 award supported mechanisms of tumor immune evasion in cervical cancer.
$1.4M
$10.3M
$2.4M
$2.6M
Most grants fall between $31K and $60K, with a median of $60K.
25th Percentile
$31K
Median
$60K
75th Percentile
$60K
DEREK ALPERT
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Concern Foundation’s typical grant size clusters tightly around $60,000, with the 25th percentile at $31,250 and both the median and 75th percentile at $60,000. That pattern fits a seed- and early-stage research model rather than large, open-ended awards. The foundation’s programs include biennial grants and a named legacy fund, and at least one program accepts unsolicited applications while others use an application and scientific review process or a pre-eligibility questionnaire before invitation. Recent grants repeat across multiple years to some institutions and project themes, indicating ongoing support rather than one-off awards in every case.
Concern Foundation’s grant recipients are entirely in the United States. California receives half of the grants, and Los Angeles appears frequently in the recent award list, including Children’s Hospital Los Angeles USC, Childrens Hospital Los Angeles, the University of Southern California, and USC Norris Comprehensive Cancer Center. Other recipient cities include Houston, Portland, Philadelphia, New York, Boston, Salt Lake City, Chicago, Columbus, St. Louis, Torrance, West Lafayette, Charleston, and Ann Arbor among the listed awards.
Concern Foundation funds laboratory and translational cancer research, especially cancer genetics, cancer cell biology, cancer immunology, and immunotherapy. Its active programs also support early-stage discovery research, including breast and women’s cancers, and projects on tumor microenvironment, metastasis, and immune evasion.
The foundation’s programs are aimed at early-career scientists, post-doctoral researchers, and junior faculty working at affiliated research institutions such as universities and nonprofit medical centers in the United States. The Conquer Cancer Now Award is specifically described as 2-year funding for early-career and post-doctoral cancer researchers.
The median grant size is $60,000, and the 75th percentile is also $60,000. The 25th percentile is $31,250, so many awards cluster at or around the $60,000 level, with some larger project grants as well.
Yes, some of its programs do. The Concern Foundation Grant Program and the Conquer Cancer Now Award both accept unsolicited applications, while the Minnie Riperton Legacy Fund is marked as not accepting unsolicited applications.
Concern Foundation gives nationally within the United States, but California is the top state by grant count. In the recent awards, Los Angeles institutions appear repeatedly, including Children’s Hospital Los Angeles, the University of Southern California, and USC Norris Comprehensive Cancer Center.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| CHILDRENS HOSPITAL LOS ANGELES | LOS ANGELES, CA | $150,000 | 2025 | NOVEL MOLECULAR MECHANISM(S) OF P1D1 FUNCTION IN PEDIATRIC BRAIN TUMORS. |
| USC NORRIS COMPREHENSIVE CANCER CENTER | LOS ANGELES, CA | $100,000 | 2025 | ETHNIC DIFFERENCES IN IMMUNE RESPONSES AMONG BREAST CANCER PATIENTS |
| CHILDREN'S HOSPITAL LOS ANGELES | LOS ANGELES, CA | $90,000 | 2025 | SUMMER ONCOLOGY RESEARCH FELLOWSHIP PROGRAM |
| THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | HOUSTON, TX | $75,000 | 2025 | TARGETING COLLAGEN I HOMOTRIMER INDUCED IL-18 AS A NOVEL THERAPEUTIC STRATEGY IN PANCREATIC CANCER |
| OREGON HEALTH & SCIENCE UNIVERSITY | PORTLAND, OR | $75,000 | 2025 | ANTIGEN SORTING BY DENDRITIC CELLS IMPACTS ANTI-TUMOR IMMUNITY |
| OREGON HEALTH AND SCIENCE UNIVERSITY | PORTLAND, OR | $75,000 | 2025 | REPROGRAMMING SUPPRESSIVE REGULATORY T CELLS IN THE TUMOR MICROENVIRONMENT |
| CHILDREN'S HOSPITAL LOS ANGELES | LOS ANGELES, CA | $75,000 | 2025 | ELUCIDATING THE MECHANISM OF CHROMOSOME 17Q GAIN-MEDIATED NEUROBLASTOMA TUMORIGENESIS |
| WASHINGTON UNIVERSITY | ST LOUIS, MO | $75,000 | 2025 | TARGETING MECHANISMS OF TUMOR IMMUNE EVASION IN CERVICAL CANCER |
| UT MD ANDERSON CANCER CENTER | HOUSTON, TX | $75,000 | 2025 | ELUCIDATING THE MOLECULAR AND CELLULAR PATHOGENESIS OF ENDOGENOUS RETROVIRUSES IN SKIN CANCER |
| TEMPLE UNIVERSITY | PHILADELPHIA, PA | $75,000 | 2025 | ROLE OF CHEMOTHERAPY IN PROMOTING AWAKENING OF DORMANT TUMOR CELLS AND METASTATIC RELAPSE |
| THE WISTAR INSTITUTE | PHILADELPHIA, PA | $75,000 | 2025 | MYELOID CELL-DERIVED INTERLEUKIN 1B PROMOTES CHEMORESISTANCE IN METASTATIC OVARIAN CANCER. |
| MEMORIAL SLOAN KETTERING CANCER CENTER | NEW YORK, NY | $75,000 | 2025 | EARLY TRANSCRIPTIONAL, EPIGENETIC, AND ENVIRONMENTAL FACTORS OF SQUAMOUS TRANSFORMATION IN LUNG CANCER |
| OHIO STATE UNIVERSITY | COLUMBUS, OH | $75,000 | 2025 | TARGETING A NEW IMMUNE CHECKPOINT AXIS (PILRCD8) TO TREAT GLIOBLASTOMA |
| U-GROW PROGRAM CEDARS SINAI MEDICAL CENTER | LOS ANGELES, CA | $50,000 | 2025 | FOR THE U GROW PROGRAM PREPARING FUTURE SCIENTISTS FOR GRADUATE SCHOOL |
| BEAUTY BUS FOUNDATION | LOS ANGELES, CA | $45,000 | 2025 | POP-UP EVENTS FOR THE CANCER COMMUNITY |
| HOPE FOR HENRY FOUNDATION | WASHINGTON, DC | $30,000 | 2025 | TO EXPAND THE HOPE FOR HENRYS HIGH-IMPACT AND IN-DEMAND SUPER REWARDS FOR SUPER KIDS PROGRAM TO ONE NEW HOSPITAL. |
| USC NORRIS HEAD & NECK CANCER | LOS ANGELES, CA | $25,000 | 2025 | TO SUPPORT A NOVEL HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IMMUNOTHERAPY STUDY USING BOTH ANIMAL MODELS AND PATIENT-DERIVED TUMOR ORGANOIDS |
| UROLOGIC HEALTH PROGRAM PROVIDENCE ST JOSEPH'S MEDICAL CENTER DISNEY FAMIL | BURBANK, CA | $25,000 | 2025 | TO COVER UROLOGIC ONCOLOGY PROGRAMS AT THE DISNEY CANCER CENTER |
| USC NORRIS COMPREHENSIVE CANCER CENTER | LOS ANGELES, CA | $25,000 | 2025 | TO EXPAND THE ADOLESCENT AND YOUNG ADULT CANCER PROGRAM AT USC |
| CHILDREN'S HOSPITAL LOS ANGELES | LOS ANGELES, CA | $25,000 | 2025 | EVALUATION OF A NOVEL CELLULAR THERAPY FOR CHILDREN AND YOUNG ADOLESCENTS WITH HIGH-GRADE GLIOMA BRAIN TUMORS |
| SHARSHERET | LOS ANGELES, CA | $25,000 | 2025 | TO COVER BUSY BOX AND THRIVING AGAIN KITS |
| CITY OF HOPE | DUARTE, CA | $22,000 | 2025 | PANCREATIC DUCTAL ADENOCARCINOMA- COLLECTING PLASMA WITH PANCREATIC CANCER AND THOSE IN HIGH RISK OF DEVELOPING THE DISEASE |
| CEDARS SINAI MEDICAL CENTER | LOS ANGELES, CA | $20,000 | 2025 | TO COVER SERVICES AND WORKSHOPS FOR THE WELLNESS, RESILIENCE, AND SURVIVORSHIP PROGRAM |
| CHILDREN'S HOSPITAL LOS ANGELES USC | LOS ANGELES, CA | $225,000 | 2024 | FLIP-FLOPPING OF FUSION-POSITIVE RHABDOMYOSARCOMA LEADING TO METASTATIC INVASION |
| UNIVERSITY OF SOUTHERN CALIFORNIA | LOS ANGELES, CA | $100,000 | 2024 | ETHNIC DIFFERENCES AMONG BREAST CANCER PATIENT IMMUNE RESPONSES |
| NYU GROSSMAN SCHOOL OF MEDICINE | NY, NY | $60,000 | 2024 | DISCOVERING AND TARGETING COQ10 SYNTHESIS IN PANCREATIC CANCER |
| BRIGHAM AND WOMEN'S HOSPITALHARVARD MEDICAL SCHOOL | BOSTON, MA | $60,000 | 2024 | OVERCOMING PARP INHIBITOR RESISTANCE BY MODULATING TUMOR ASSOCIATED MACROPHAGES TO ENHANCE T CELL ACTIVATION |
| THE LUNDQUIST INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | TORRANCE, CA | $60,000 | 2024 | INVESTIGATING NOVEL SIGNALING CIRCUITS CONTROLLING PDL1 SURFACE LOCALIZATION IN CANCER CELLS. |
| CHILDREN'S HOSPITAL LOS ANGELES USC | LOS ANGELES, CA | $60,000 | 2024 | FLIP-FLOPPING OF FUSION-POSITIVE RHABDOMYOSARCOMA LEADING TO METASTATIC INVASION |
| UNIVERSITY OF SOUTHERN CALIFORNIA | LOS ANGELES, CA | $60,000 | 2024 | EXPANSION OF THE ADOLESCENT AND YOUNG ADULT CANCER PROGRAM AT USC |
| THE UNIVERSITY OF ILLINOIS AT CHICAGO | CHICAGO, IL | $60,000 | 2024 | REGULATION OF MECHANOSURVEILLANCE BY K HANDLING DURING BREAST CANCER METASTASIS |
| UNIVERSITY OF UTAH | SALT LAKE CITY, UT | $60,000 | 2024 | TENASCIN-C IN EARLY LUNG CANCER INVASION |
| PURDUE UNIVERSITY | WEST LAFAYETTE, IN | $60,000 | 2024 | THE ROLE OF PP2A IN REGULATING PDAC METHUOSIS |
| BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE | DUARTE, CA | $60,000 | 2024 | TARGETING THE LONG ISOFORM OF THE PROLACTIN RECEPTOR IN B CELL MALIGNANCIES |
| UNIVERSITY OF MICHIGAN | ANN ARBOR, MI | $60,000 | 2024 | REGULATING JAK-STAT SIGNALING PATHWAYS TO ENHANCE T CELL IMMUNOTHERAPY |
| WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST LOUIS | ST LOUIS, MO | $60,000 | 2024 | INVESTIGATE THE TUMOR SUPPRESSIVE ROLE OF ARID HOMOLOGS IN MELANOMA |
| CEDARS SINAI | LOS ANGELES, CA | $50,000 | 2024 | U-GROW PROGRAM |
| SHARSHERET | TEANECK, NJ | $25,000 | 2024 | BUSY BOX AND THRIVING AGAIN KITS |
| CHLA SUMMER ONCOLOGY | LOS ANGELES, CA | $25,000 | 2024 | SUMMER ONCOLOGY RESEARCH FELLOWSHIP |
| PROVIDENCE | BURBANK, CA | $25,000 | 2024 | UROLOGIC ONCOLOGY PROGRAMS AT THE DISNEY CANCER CENTER |
| UNIVERSITY OF SOUTHERN CALIFORNIA | LOS ANGELES, CA | $23,500 | 2024 | EXPANSION OF THE ADOLESCENT AND YOUNG ADULT CANCER PROGRAM AT USC |
| CEDARS SINAI | LOS ANGELES, CA | $20,000 | 2024 | WELLNESS, RESILIENCE, AND SURVIVORSHIP PROGRAM |
| CITY OF HOPE | DUARTE, CA | $9,000 | 2024 | PANCREATIC DUCTAL ADENOCARCINOMA- COLLECTING PLASMA WITH PANCREATIC CANCER AND THOSE IN HIGH RISK OF DEVELOPING THE DISEASE |
| HOPE FOR HENRY | WASHINGTON, DC | $2,281 | 2024 | EXPANSION OF THE HOPE FOR HENRYS HIGH-IMPACT AND IN-DEMAND SUPER REWARDS FOR SUPER KIDS PROGRAM TO ONE NEW HOSPITAL |
| UNIVERSITY OF SOUTHERN CALIFORNIA | LOS ANGELES, CA | $100,000 | 2023 | RESEARCH INTO ETHNIC DIFFERENCES AMONG BREAST CANCER PATIENT IMMUNE RESPONSES |
| NYU GROSSMAN SCHOOL OF MEDICINE | NEW YORK, NY | $60,000 | 2023 | DISCOVERING AND TARGETING COQ10 SYNTHESIS IN PANCREATIC CANCER |
| PURDUE UNIVERSITY | WEST LAFAYETTE, IN | $60,000 | 2023 | THE ROLE OF PP2A IN REGULATING PDAC METHUOSIS |
| MEDICAL UNIVERSITY OF SOUTH CAROLINA | CHARLESTON, SC | $60,000 | 2023 | KRASG12R ALLELE-SPECIFIC METABOLIC REPROGRAMMING ALTERS THERAPEUTIC SENSITIVITY |
| THE LUNDQUIST INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | TORRANCE, CA | $60,000 | 2023 | INVESTIGATING NOVEL SIGNALING CIRCUITS CONTROLLING PDL1 SURFACE LOCALIZATION IN CANCER CELLS. |
| UNIVERSITY OF UTAH | SALT LAKE CITY, UT | $60,000 | 2023 | TENASCIN-C IN EARLY LUNG CANCER INVASION |
CHILDRENS HOSPITAL LOS ANGELES
$150,000NOVEL MOLECULAR MECHANISM(S) OF P1D1 FUNCTION IN PEDIATRIC BRAIN TUMORS.
USC NORRIS COMPREHENSIVE CANCER CENTER
$100,000ETHNIC DIFFERENCES IN IMMUNE RESPONSES AMONG BREAST CANCER PATIENTS
SUMMER ONCOLOGY RESEARCH FELLOWSHIP PROGRAM
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
$75,000TARGETING COLLAGEN I HOMOTRIMER INDUCED IL-18 AS A NOVEL THERAPEUTIC STRATEGY IN PANCREATIC CANCER
ANTIGEN SORTING BY DENDRITIC CELLS IMPACTS ANTI-TUMOR IMMUNITY
REPROGRAMMING SUPPRESSIVE REGULATORY T CELLS IN THE TUMOR MICROENVIRONMENT
ELUCIDATING THE MECHANISM OF CHROMOSOME 17Q GAIN-MEDIATED NEUROBLASTOMA TUMORIGENESIS
TARGETING MECHANISMS OF TUMOR IMMUNE EVASION IN CERVICAL CANCER
UT MD ANDERSON CANCER CENTER
$75,000ELUCIDATING THE MOLECULAR AND CELLULAR PATHOGENESIS OF ENDOGENOUS RETROVIRUSES IN SKIN CANCER
ROLE OF CHEMOTHERAPY IN PROMOTING AWAKENING OF DORMANT TUMOR CELLS AND METASTATIC RELAPSE
THE WISTAR INSTITUTE
$75,000MYELOID CELL-DERIVED INTERLEUKIN 1B PROMOTES CHEMORESISTANCE IN METASTATIC OVARIAN CANCER.
MEMORIAL SLOAN KETTERING CANCER CENTER
$75,000EARLY TRANSCRIPTIONAL, EPIGENETIC, AND ENVIRONMENTAL FACTORS OF SQUAMOUS TRANSFORMATION IN LUNG CANCER
OHIO STATE UNIVERSITY
$75,000TARGETING A NEW IMMUNE CHECKPOINT AXIS (PILRCD8) TO TREAT GLIOBLASTOMA
FOR THE U GROW PROGRAM PREPARING FUTURE SCIENTISTS FOR GRADUATE SCHOOL
TO EXPAND THE HOPE FOR HENRYS HIGH-IMPACT AND IN-DEMAND SUPER REWARDS FOR SUPER KIDS PROGRAM TO ONE NEW HOSPITAL.
USC NORRIS HEAD & NECK CANCER
$25,000TO SUPPORT A NOVEL HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IMMUNOTHERAPY STUDY USING BOTH ANIMAL MODELS AND PATIENT-DERIVED TUMOR ORGANOIDS
UROLOGIC HEALTH PROGRAM PROVIDENCE ST JOSEPH'S MEDICAL CENTER DISNEY FAMIL
$25,000TO COVER UROLOGIC ONCOLOGY PROGRAMS AT THE DISNEY CANCER CENTER
USC NORRIS COMPREHENSIVE CANCER CENTER
$25,000TO EXPAND THE ADOLESCENT AND YOUNG ADULT CANCER PROGRAM AT USC
EVALUATION OF A NOVEL CELLULAR THERAPY FOR CHILDREN AND YOUNG ADOLESCENTS WITH HIGH-GRADE GLIOMA BRAIN TUMORS
CITY OF HOPE
$22,000PANCREATIC DUCTAL ADENOCARCINOMA- COLLECTING PLASMA WITH PANCREATIC CANCER AND THOSE IN HIGH RISK OF DEVELOPING THE DISEASE
TO COVER SERVICES AND WORKSHOPS FOR THE WELLNESS, RESILIENCE, AND SURVIVORSHIP PROGRAM
CHILDREN'S HOSPITAL LOS ANGELES USC
$225,000FLIP-FLOPPING OF FUSION-POSITIVE RHABDOMYOSARCOMA LEADING TO METASTATIC INVASION
UNIVERSITY OF SOUTHERN CALIFORNIA
$100,000ETHNIC DIFFERENCES AMONG BREAST CANCER PATIENT IMMUNE RESPONSES
NYU GROSSMAN SCHOOL OF MEDICINE
$60,000DISCOVERING AND TARGETING COQ10 SYNTHESIS IN PANCREATIC CANCER
BRIGHAM AND WOMEN'S HOSPITALHARVARD MEDICAL SCHOOL
$60,000OVERCOMING PARP INHIBITOR RESISTANCE BY MODULATING TUMOR ASSOCIATED MACROPHAGES TO ENHANCE T CELL ACTIVATION
THE LUNDQUIST INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
$60,000INVESTIGATING NOVEL SIGNALING CIRCUITS CONTROLLING PDL1 SURFACE LOCALIZATION IN CANCER CELLS.
CHILDREN'S HOSPITAL LOS ANGELES USC
$60,000FLIP-FLOPPING OF FUSION-POSITIVE RHABDOMYOSARCOMA LEADING TO METASTATIC INVASION
UNIVERSITY OF SOUTHERN CALIFORNIA
$60,000EXPANSION OF THE ADOLESCENT AND YOUNG ADULT CANCER PROGRAM AT USC
THE UNIVERSITY OF ILLINOIS AT CHICAGO
$60,000REGULATION OF MECHANOSURVEILLANCE BY K HANDLING DURING BREAST CANCER METASTASIS
UNIVERSITY OF UTAH
$60,000TENASCIN-C IN EARLY LUNG CANCER INVASION
PURDUE UNIVERSITY
$60,000THE ROLE OF PP2A IN REGULATING PDAC METHUOSIS
BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE
$60,000TARGETING THE LONG ISOFORM OF THE PROLACTIN RECEPTOR IN B CELL MALIGNANCIES
UNIVERSITY OF MICHIGAN
$60,000REGULATING JAK-STAT SIGNALING PATHWAYS TO ENHANCE T CELL IMMUNOTHERAPY
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST LOUIS
$60,000INVESTIGATE THE TUMOR SUPPRESSIVE ROLE OF ARID HOMOLOGS IN MELANOMA
CEDARS SINAI
$50,000U-GROW PROGRAM
SHARSHERET
$25,000BUSY BOX AND THRIVING AGAIN KITS
CHLA SUMMER ONCOLOGY
$25,000SUMMER ONCOLOGY RESEARCH FELLOWSHIP
PROVIDENCE
$25,000UROLOGIC ONCOLOGY PROGRAMS AT THE DISNEY CANCER CENTER
UNIVERSITY OF SOUTHERN CALIFORNIA
$23,500EXPANSION OF THE ADOLESCENT AND YOUNG ADULT CANCER PROGRAM AT USC
CEDARS SINAI
$20,000WELLNESS, RESILIENCE, AND SURVIVORSHIP PROGRAM
CITY OF HOPE
$9,000PANCREATIC DUCTAL ADENOCARCINOMA- COLLECTING PLASMA WITH PANCREATIC CANCER AND THOSE IN HIGH RISK OF DEVELOPING THE DISEASE
HOPE FOR HENRY
$2,281EXPANSION OF THE HOPE FOR HENRYS HIGH-IMPACT AND IN-DEMAND SUPER REWARDS FOR SUPER KIDS PROGRAM TO ONE NEW HOSPITAL
UNIVERSITY OF SOUTHERN CALIFORNIA
$100,000RESEARCH INTO ETHNIC DIFFERENCES AMONG BREAST CANCER PATIENT IMMUNE RESPONSES
NYU GROSSMAN SCHOOL OF MEDICINE
$60,000DISCOVERING AND TARGETING COQ10 SYNTHESIS IN PANCREATIC CANCER
PURDUE UNIVERSITY
$60,000THE ROLE OF PP2A IN REGULATING PDAC METHUOSIS
MEDICAL UNIVERSITY OF SOUTH CAROLINA
$60,000KRASG12R ALLELE-SPECIFIC METABOLIC REPROGRAMMING ALTERS THERAPEUTIC SENSITIVITY
THE LUNDQUIST INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
$60,000INVESTIGATING NOVEL SIGNALING CIRCUITS CONTROLLING PDL1 SURFACE LOCALIZATION IN CANCER CELLS.
UNIVERSITY OF UTAH
$60,000TENASCIN-C IN EARLY LUNG CANCER INVASION